Discussion
Both first-line and second-line SLT significantly reduced IOP in Japanese patients with NTG during 12 months of follow-up. Post-SLT IOP values and IOP reduction were comparable between the two groups. A higher IOP and thinner CCT prior to SLT were identified as factors associated with a greater SLT-induced reduction in IOP in NTG patients. The success rate at 12 months was higher in the first-line group than the second-line group, with lower pretreatment IOP and use of IOP-lowering eye-drops before SLT identified as factors related to treatment failure. Post-treatment complications were mostly minor and transient.
Our findings were consistent with previous studies that showed a substantial reduction in IOP after first-line SLT for NTG. In a study of Japanese patients with NTG including 37 treatment-naïve patients and 5 patients who had discontinued IOP-lowering medications before SLT, we found that the pretreatment mean IOP of 15.8 mm Hg was significantly reduced by 15.8% to 13.2 mm Hg at 1 year after first-line SLT, and by 12.7% to 13.5 mm Hg at 3 years, while 25% of the subjects started IOP-lowering eye-drops after first-line SLT and 15.0% underwent SLT retreatment.11 Lee et al evaluated a single session of SLT in medicated patients with NTG after a 1-month washout of IOP-lowering eye-drops.13 They reported that the mean IOP was 12.2 mm Hg and mean number of eye-drops was 1.1 at 1 year after a single session of SLT, which resulted in an additional 15% reduction in IOP while using 27% less medication. The success rate was 22%, when success was defined as an IOP reduction ≥20% from pre-SLT without any additional IOP-lowering eye-drops at 1 year.13 In their 2-year study, they found a reduction in IOP of 22.0% from pre-SLT IOP and a medication decrease of 41.1% after initial SLT and a success rate of 11.1% at 2 years, using the same success criteria as at 1 year.10 In the LiGHT trial, the SLT group showed better adherence and consequently better QOL. In terms of cost, SLT was more cost-effective than IOP-lowering eye-drops.1 SLT is expected to improve symptoms related to ocular surface diseases and improve adherence to the remaining medications.
According to the Guidelines on Design and Reporting of Glaucoma Surgical Trials issued by the World Glaucoma Association,14 the success rate for NTG, defined by a 20% reduction in IOP, is lower than that for POAG because the baseline IOP falls within the normal range. Notably, patients treated with three to four types of IOP-lowering eye-drops with a preoperative IOP of 18 mm Hg and postoperative IOP of 15 mm Hg, may be categorised as treatment failures. In the current study, we, therefore, also determined the ΔOP to evaluate the treatment outcomes for patients with NTG, with response defined as ΔOP≥20% for SLT. For example, if a patient’s IOP decreased from 13 mm Hg before SLT to 11 mm Hg after SLT, it would be beneficial for glaucoma treatment. However, the percentage reduction in IOP was only 15.3%, and this IOP-lowering effect was underestimated with respect to its clinical significance. Therefore, we considered the usual success criteria undesirable. A study examining outflow facilities before and after SLT12 reported that only outflow facilities increased significantly after SLT with no changes in aqueous humour flow rate (Q), uveoscleral outflow (U) or EVP. To assess the outflow facility, we included the ΔOP as an endpoint to better evaluate the IOP-lowering effect of the SLT. Since EVP=10 mm Hg was assumed for the calculation of ΔOP, a low IOP close to EVP still has the problem of underestimation of the effect of SLT. Therefore, patients were not included in the study unless their IOP was 14 mm Hg or higher. In addition, in practice, a large IOP-reducing effect cannot be expected in cases with extremely low preoperative IOP.
First-line or second-line SLT for NTG was deemed beneficial in this study, with an average reduction in IOP of 16.0% at 12 months. The scatter plot (online supplemental files figure 1) demonstrates that numerous patients achieved a reduction in IOP of ≥20%. Although the success rate based on criterion B was low (19.2%), the success rate according to criterion A, which assessed ΔOP, was 83.8%, suggesting that ΔOP is a valuable metric for evaluating treatment outcomes in patients with NTG.
Comparing first-line and second-line SLT, although the rate of IOP reduction was higher in the first-line compared with the second-line group at 6 months, the post-treatment IOP values and reduction rates were comparable between the two groups at other time points. However, the success rate at 12 months was higher in the first-line group than in the second-line group (23.0% vs 8.0%, respectively). These results were in line with previous reports. Woo et al15 retrospectively evaluated the additional effect of SLT in patients with POAG, OHT, exfoliation glaucoma or pigmentary glaucoma, classified into four groups according to the number of pre-SLT IOP-lowering medications (0–3) and followed up for 5 years. They showed that although the number of pre-SLT eye-drops did not affect the IOP-lowering effect of SLT, a higher proportion of patients receiving more medications required additional interventions such as trabeculectomy, SLT or additional medications. The increased need for additional interventions or medications in patients with more pre-SLT medications may be the result of the limited response to SLT due to the reduced natural capacity of the patient’s trabecular meshwork and physiological outflow caused by prior treatment with topical aqueous suppressants.16 The current study also revealed that use of IOP-lowering eye-drops before SLT was one of the factors related to treatment failure at 12 months post-SLT. Patients who received eye-drops before SLT (ie, the second-line group) had lower pre-SLT IOP values, which may have reduced the success rate. Treatment-naïve patients with NTG were more likely to respond favourably to SLT than medically treated patients, in accord with previous results in patients with POAG or OHT.1–5
The IOP-lowering effect of 17.1% for first-line SLT in the current study is unlikely to be sufficient to achieve drop-free IOP control in patients with newly diagnosed NTG, given an individual IOP target of a 30% reduction from baseline IOP indicated by the Collaborative Normal Tension Glaucoma study.17 Nevertheless, Kashiwagi et al18 assessed the long-term effect of latanoprost monotherapy in Japanese patients with glaucoma, including 65% with NTG, and demonstrated that it reduced IOP by 15.5%, which was equivalent to the IOP-lowering effect of first-line SLT in this study. In addition, El Mallah et al found that adjunctive SLT decreased mean IOP by 14.7% and also reduced intervisit variations in IOP in patients with NTG.19 SLT may, thus, help to prevent glaucoma progression by reducing IOP fluctuations,20–23 as well as improving treatment adherence and patient QOL, by decreasing the number of IOP-lowering eye-drops in patients with NTG.
In this study, higher IOP and thinner CCT before SLT were identified as factors associated with a greater reduction in IOP at 1 year. In addition, a lower IOP and use of IOP-lowering eye-drops before SLT were factors related to failure at 1 year. Previous studies have suggested that a higher pre-SLT IOP may be a predictor of a successful outcome in patients with POAG.16 24 25 The LiGHT trial demonstrated that first-line SLT was more likely to be effective in female patients, patients with higher pretreatment IOP, and those with mild POAG or OHT. A high energy of SLT irradiation and low IOP at 2 months after SLT were also shown to sustain a long-term IOP-reduction rate ≥20%.2 Regarding NTG, Lee et al13 studied 60 eyes in medicated patients with NTG after a 1-month washout of medication, and showed that a higher pre-SLT IOP and a greater IOP reduction at 1 week post-SLT were predictors of a successful outcome. As stated in the Guidelines on Design and Reporting of Glaucoma Surgical Trials published, the success rate for NTG, defined as an IOP reduction ≥20%, is lower than the success rate for POAG. This difference is attributed to baseline IOP values being within the normal range. Therefore, a higher pre-SLT IOP was also associated with a greater IOP reduction and a higher success rate in this study.14 The factors associated with success of SLT may differ between NTG and POAG.
Complications after SLT include transient IOP spike, anterior chamber haemorrhage, iritis, ME and corneal oedema.26–32 There were no cases of a transient IOP increase ≥5 mm Hg in the current study. After SLT, 43.4% of patients in this study reported ocular discomfort, headache, blurred vision, photophobia and nausea, all of which were transient symptoms. One patient had ME due to macular BRVO, but this resolved within 3 months without treatment, and we failed to identify any causal relationship between SLT and BRVO. Because transient corneal endothelial cell damage has been reported following SLT,28 33 we also examined the ECD after SLT and found no significant decrease in this parameter between pre-SLT and 1-year post-SLT.
This study had several limitations. First, we were unable to determine the long-term IOP-lowering effects of first-line and second-line SLT because the observation period was only 1 year, and further interventions may be required to maintain long-term IOP control. We aim to analyse the long-term SLT outcomes of the participants in this study. Second, there is no control group, and the clinical backgrounds of the two groups are different.
This prospective study was designed to evaluate the efficacy and safety of SLT in patients who were to undergo SLT as either first-line or second-line treatment. In the real world of glaucoma, the second line of patients undergo SLT for a longer period of time and with more advanced stage than the first-line SLT groups. In Japan, IOP-lowering eye-drops remain the first-line treatment in most glaucoma cases. For patients with poorly controlled glaucoma, the target IOP is set even lower, and additional treatment is administered, which often leads to adverse events caused by the IOP-lowering eye-drops (eg, allergy, superficial punctate keratopathy, bradycardia and chronic obstructive pulmonary disease). This indicates that the patients eligible for second-line SLT included those with varied clinical backgrounds. Further IOP reduction with SLT in such patients would be clinically ‘beneficial’ and is highly expected to ‘delay’ the surgical decision. Therefore, patients in the second-line SLT group were included in this study.
In conclusion, both first-line and second-line SLT may be effective and safe treatments for patients with NTG, leading to a substantial decrease in IOP over a period of 1 year, with no serious adverse events. Further investigations are warranted to identify the long-term efficacy of first-line and second-line SLT in patients with NTG.